Moderna Gets OK to Increase Doses in COVID-19 Vaccine Vials
FRIDAY, April 2, 2021 -- Moderna has been authorized to put 50 percent more COVID-19 vaccine into its vials, the U.S. Food and Drug Administration said Thursday.
The company had already started producing fuller vials (15 doses instead of 10) in anticipation of the approval and said in a statement that it expects to begin shipping the 15-dose vials within weeks.
The FDA approval provides fresh assurance about the supply of the Moderna two-dose vaccine. The company has promised to deliver 200 million doses by the end of May and 300 million by the end of July.
Approval of the fuller vials comes a day after it was announced that a production error ruined up to 15 million doses of the Johnson & Johnson single-dose vaccine, which delayed FDA authorization of the Baltimore plant where that vaccine is being manufactured.
All shipments from the plant have been delayed until the FDA completes its investigation and decides whether to approve vaccine production at the plant. Even, so Johnson & Johnson says it will still be able to deliver its promised 24 million doses of vaccine this month.
© 2021 HealthDay. All rights reserved.
Posted: April 2021
Further Support and Information on COVID-19
Read this next
MONDAY, April 19, 2021 -- The official global COVID-19 death toll surpassed 3 million this weekend, according to Johns Hopkins University data. But the actual number of people...
MONDAY, April 19, 2021 -- Moderna says a third booster shot for its two-dose COVID-19 vaccine will be available in the United States by the fall. The announcement was made by...
MONDAY, April 19, 2021 -- An indefinite extension on wearing masks and social distancing in all businesses is being considered by the administrator of the Oregon Department of...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.